Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

Fig. 1

TNFα gene expression signature in leukemic stem and progenitor cells. a Gene Set Enrichment Analysis (GSEA) pathway analysis was performed from previously published microarray data (GSE# 18446) that were obtained from SCLtTA/Bcr-Abl and control LSK (lin; Sca-1+; c-kit+) cells (n = 3/3). b Expression of TNFα was evaluated in a further set of murine SCLtTA/Bcr-Abl and control LSK cells by qRT-PCR (n = 3/3). c qRT-PCR analysis of TNFα in total BM cells from murine SCLtTA/Bcr-Abl and control mice (n = 3/3). d TNFα expression was assessed in 32D:EV, 32D:Bcr-Abl, BA/F3:EV and BA/F3:Bcr-Abl cells. e Human erythroleukemic cell line TF-1 was transduced with EV and Bcr-Abl and subsequently analyzed for TNFα expression by qRT-PCR. f HoxB8 immortalized progenitor BM cells from SCLtTA/Bcr-Abl mice were treated with MP6-XT22 (2 μg/ml), 100 nM nilotinib or the combination of both agents in the presence of 0.05 ng/ml TNFα. Protein expression was analyzed using western blot. g Expression of the NF-кB target gene A20 was analyzed in HoxB8 immortalized progenitor BM cells from SCLtTA/Bcr-Abl mice upon Bcr-Abl inhibition using nilotinib (100 nM) in the absence and presence of 0.05 ng/ml TNFα. h TNFα expression was analyzed in 32D:Bcr-Abl cells upon imatinib (IM, 5 μM) treatment and i in LSK cells from SCLtTA/Bcr-Abl mice that had been induced to express Bcr-Abl for 25 days and were then reverted to not express the oncogene for 48 days. (n.s. = not significant, ***p < 0.001)

Back to article page